Geoffrey Loh, MD
Critical Care Medicine · Cincinnati, OHNPI 1043504129
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.9%), education and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Intuitive Surgical at 50.0% of the total. Reporting peaked in 2024 at $4,743 and has fallen 55.2% since, to $2,127 in 2025. Among critical care medicine clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $35.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$923
- AstraZeneca$774
- Sanofi$364
- Insmed, Inc.$209
- Verona Pharma, Inc.$179
- plus $1K from 19 others
What the payments were for
- Consulting fees$501%
- Travel & lodging$1,00414%
- Food & beverage$3,37048%
- Education$2,61737%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $3,521 |
| GSK | 67 | $923 |
| AstraZeneca | 26 | $774 |
| Sanofi | 22 | $364 |
| Insmed, Inc. | 13 | $209 |
| Verona Pharma, Inc. | 10 | $179 |
| Grifols USA, LLC | 8 | $167 |
| Boehringer Ingelheim | 8 | $152 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $97 |
| Regeneron Healthcare Solutions, Inc. | 5 | $81 |
| Mylan Specialty L.p. | 5 | $80 |
| Philips North America LLC | 3 | $71 |
| Viatris Specialty LLC | 4 | $64 |
| Genentech USA, Inc. | 2 | $43 |
| Inogen, Inc. | 3 | $38 |
| Vifor Pharma, Inc. | 1 | $26 |
| Baxter Healthcare | 1 | $26 |
| QOL Medical, LLC | 1 | $22 |
| Electromed, Inc. | 2 | $20 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Pulmonx Corporation | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,479
- BREZTRI$236
- AIRSUPRA$236
- FASENRA$236
- TEZSPIRE$236
How this compares
$7,042 in reported general payments places this provider in the 90th percentile of 285 critical care medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pirfenidone | 12 | $56,678 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $55,815 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $22,020 |
| Spiriva RespimatTiotropium Bromide | 32 | $21,940 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $15,734 |
| Arnuity ElliptaFluticasone Furoate | 14 | $6,414 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $5,463 |
| Varenicline Tartrate | 22 | $4,163 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 123 | $2,599 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,475 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,433 |
| Ipratropium Bromide | 20 | $795 |
| Azithromycin | 19 | $238 |
| Prednisone | 49 | $206 |
| Montelukast Sodium | 16 | $153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $923 | $77,962105 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $774 | $27,48342 claims |
| Boehringer IngelheimSpiriva Respimat | $152 | $21,94032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 285 critical care medicine providers in Ohio.
Other critical care medicine in Cincinnati
- Sadia BenzaquenCincinnati$15K
- Maria IndiharCincinnati$8K
- Kiranmayee LankaCincinnati$6K
- Thomas PrestonCincinnati$5K
- Muhammad KhawarCincinnati$5K
- Christopher OrabellaCincinnati$5K
- Adam ColeCincinnati$4K
- Christopher SchmittCincinnati$4K
- Eric WeinsteinCincinnati$4K
- Jonathan HendersonCincinnati$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.